Public Employees Retirement System of Ohio Invests $7.86 Million in Illumina, Inc. $ILMN

Public Employees Retirement System of Ohio bought a new stake in Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 44,725 shares of the life sciences company’s stock, valued at approximately $7,864,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. HighPoint Advisor Group LLC increased its stake in Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after purchasing an additional 80 shares during the period. Elevation Wealth Partners LLC boosted its stake in shares of Illumina by 52.5% during the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares during the period. Meeder Advisory Services Inc. boosted its stake in shares of Illumina by 3.1% during the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after purchasing an additional 85 shares during the period. Toronto Dominion Bank grew its holdings in shares of Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after purchasing an additional 92 shares during the last quarter. Finally, Panagora Asset Management Inc. grew its holdings in shares of Illumina by 3.9% in the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after purchasing an additional 96 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Down 3.0%

Shares of Illumina stock opened at $207.13 on Wednesday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $231.81. The company has a market cap of $31.28 billion, a P/E ratio of 38.64, a PEG ratio of 3.01 and a beta of 1.46. The company’s fifty day simple moving average is $195.94 and its two-hundred day simple moving average is $157.18.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the company posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price target on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Guggenheim boosted their price objective on shares of Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft downgraded shares of Illumina to a “hold” rating in a research note on Wednesday, August 5th. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Thursday, May 14th. Finally, Royal Bank Of Canada boosted their price target on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $188.40.

Insiders Place Their Bets

In other news, Director Keith A. Meister sold 138,379 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $228.89, for a total value of $31,673,569.31. Following the completion of the transaction, the director owned 1,033,910 shares of the company’s stock, valued at approximately $236,651,659.90. This represents a 11.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,799,688 shares of company stock worth $379,517,231 over the last three months. Company insiders own 2.90% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.